CJC-1295 DAC
Also known as · CJC-1295 with Drug Affinity Complex · long-acting GHRH analogue (ConjuChem)
- EvidenceClinical
- CategoryGHRH
- RoutesubQ
- Half-life5.8–8.1 days
01 / Dosing schedule
Cited dosing
CJC-1295 with DAC has real, published human pharmacology from two randomized placebo-controlled ascending-dose trials in healthy adults, but it was never developed past that stage and is not FDA approved. The doses explicitly reported in the abstract are 30 and 60 microg/kg subcutaneously.
Teichman 2006 ascending-dose trials — subQ CJC-1295 in healthy adults
| Phase | Dose & frequency |
|---|---|
| Single-dose reported doses | 30 microg/kg and 60 microg/kg subcutaneously |
| Other single-dose levels | n.a. — abstract says 'four ascending single doses' without listing the other two |
| Multiple-dose study | two or three doses given weekly or biweekly (dose amounts n.a. in the abstract) |
| Study durations | 28 days and 49 days |
| Measured half-life | 5.8-8.1 days |
Source indication · Pharmacokinetics, pharmacodynamics (GH and IGF-I) and safety in healthy adults aged 21-61 — not a disease indication
- Injection frequency
- Single dose in study 1; two or three doses at weekly or every-other-week intervals in study 2 (28-day and 49-day studies).
- Injection sites
- n.a. — the trial report states subcutaneous administration only; no anatomical injection site is given.
02 / Reconstitution
Reconstitution reference
The 2006 trials do not publish a reconstitution procedure. Because trial dosing was weight-based (microg/kg), any vial arithmetic must be done per subject weight; the values below are unit-conversion arithmetic only and are not a dose recommendation.
03 / Overview
Protocol overview
CJC-1295 is GHRH(1-29) modified with a Drug Affinity Complex that lets it bind covalently to serum albumin after injection. That is the mechanism behind the measured half-life of 5.8-8.1 days reported by Teichman and colleagues in JCEM in 2006.
The human evidence base is two randomized, placebo-controlled, double-blind ascending-dose trials of 28 and 49 days at two investigational sites, in healthy subjects aged 21-61. The first gave four ascending single subcutaneous doses; the second gave two or three doses weekly or biweekly.
Only two dose levels appear in the public abstract: 30 microg/kg and 60 microg/kg, at which mean peak GH and IGF-I rose above baseline. The remaining two ascending dose levels, and the exact repeat-dose amounts, are not in the abstract, so they are recorded as n.a. rather than reproduced from secondary peptide sites.
Nothing since 2006 has taken CJC-1295 DAC into phase 2 or phase 3 for a defined indication. There is no approved product, no label, and no dosing guidance from any regulator; the trial figures above are pharmacology data in healthy volunteers, not a therapeutic regimen.
04 / References